clinical pipeline

Clinical Pipeline

CLINICAL PIPELINE

Indication View
Molecule View
Indication
Study
Line & Regimena,b
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Indication:

NSCLC

Line & Regimena,b :
WT 1L, PD-L1 ≥ 50% ,  
dom + zim ± etruma
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Line & Regimena,b :
EGFRm 2L+ ,  
etruma + zim + carbo/pem
Phase 1
Phase 1b
Randomized/
Phase 2
Pivtotal/
Phase 3
Line & Regimena,b :
WT 1L, PD-L1 ≥ 50% ,  
dom + zim vs. zim vs. chemo
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Indication:

mCRPC

Line & Regimena,b :
1L ,  
etruma + zim + enza
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Line & Regimena,b :
2L+ ,  
etruma + zim + doce
Phase 1
Phase 1b
Randomized/
Phase 2
Pivtotal/
Phase 3
Line & Regimena,b :
2L+ ,  
etruma + zim
Phase 1
Phase 1b
Randomized/
Phase 2
Pivtotal/
Phase 3
Line & Regimena,b :
2L+ ,  
etruma + zim + AB680
Phase 1
Phase 1b
Randomized/
Phase 2
Pivtotal/
Phase 3
Indication:

CRC

Line & Regimena,b :
2L ,  
etruma + zim + FOLFOX* vs. FOLFOX*
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Line & Regimena,b :
3L ,  
etruma + zim + FOLFOX* vs. Rego
Phase 1
Phase 1b
Randomized/
Phase 2
Pivtotal/
Phase 3
Line & Regimena,b :
>3L ,  
etruma combinations
Phase 1
Phase 1b
Randomized/
Phase 2
Pivtotal/
Phase 3
Indication:

PDAC

Line & Regimena,b :
1L ,  
AB680 + zim + gem/nab-pac
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Indication:

Advanced Malignancies

Line & Regimena,b :
,  
AB308 + zim
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Moleculea,b
Indication
Study
Line & Regimen
Phase 1
Phase 1b
Phase 2
Phase 3
Moleculea,b :

Domvanalimab
(DOM)

Anti-TIGIT Antibody

Indication:

NSCLC

Line & Regimen:
1L ,  
dom + zim ± etruma
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

NSCLC

Line & Regimen:
WT 1L, PD-L1 ≥ 50% ,  
dom + zim vs. zim vs. chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Multiple Cancer Types

Line & Regimen:
2L+ ,  
dom + zim
Phase 1
Phase 1b
Phase 2
Phase 3
Moleculea,b :

AB308

Indication:

Advanced Malignancies

Line & Regimen:
,  
AB308 + zim
Phase 1
Phase 1b
Phase 2
Phase 3
Moleculea,b :

AB680

CD73 Inhibitor Small Molecule

Indication:

PDAC

Line & Regimen:
1L ,  
AB680 + zim + gem/nab-pac
Phase 1
Phase 1b
Phase 2
Phase 3
Moleculea,b :

Etrumadenant
(ETRUMA)

Dual A2a/A2b Adenosine Receptor Antagonist Small Molecule

Indication:

CRPC

Line & Regimen:
1L+ ,  
etruma + zim ± enza
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

CRPC

Line & Regimen:
2L+ ,  
etruma + zim + doce
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

CRPC

Line & Regimen:
2L+ ,  
etruma + zim
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

CRPC

Line & Regimen:
2L+ ,  
etruma + zim + AB680
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

CRC

Line & Regimen:
2L ,  
etruma + zim + FOLFOX* vs. FOLFOX*
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

CRC

Line & Regimen:
3L ,  
etruma + zim + FOLFOX* vs. Rego
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

CRC

Line & Regimen:
>3L ,  
etruma combinations
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

NSCLC

Line & Regimen:
EGFRm 2L+ ,  
dom + zim + carbo/pem
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

NSCLC

Line & Regimen:
1L ,  
dom + zim ± etruma
Phase 1
Phase 1b
Phase 2
Phase 3


Etrumadenant: Dual A2aR/A2bR Antagonist Small Molecule
AB680: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.

ABBREVIATIONS:
Dom: domvanalimab; Etruma: etrumadenant; Zim: zimberelimab; Doce: docetaxel; Enza: enzalutamide; Atezo: atezolizumab; Rego: regorafenib; Carbo/Pem: carboplatin/pemetrexed; Bev: bevacizumab; Gem/Nab-pac: gemcitabine/nab-paclitaxel; PLD: pegylated liposomal doxorubicin; SOC: standard of care

CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma;

PARTNERSHIPS & COLLABORATIONS:

gilead logo (a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.

taiho logo (b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).

||Clinical collaboration with Infinity Pharmaceuticals.
*+/- biologic


Etrumadenant: Dual A2aR/A2bR Antagonist Small Molecule
AB680: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.

ABBREVIATIONS:
Dom: domvanalimab; Etruma: etrumadenant; Zim: zimberelimab; Doce: docetaxel; Enza: enzalutamide; Atezo: atezolizumab; Rego: regorafenib; Carbo/Pem: carboplatin/pemetrexed; Bev: bevacizumab; Gem/Nab-pac: gemcitabine/nab-paclitaxel; PLD: pegylated liposomal doxorubicin; SOC: standard of care

CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma;

PARTNERSHIPS & COLLABORATIONS:

gilead logo (a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.

taiho logo (b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).

||Clinical collaboration with Infinity Pharmaceuticals.
*+/- biologic